FY2025 Earnings Forecast for DRUG Issued By Chardan Capital

Bright Minds Biosciences Inc. (NASDAQ:DRUG) – Chardan Capital issued their FY2025 earnings estimates for Bright Minds Biosciences in a research report issued to clients and investors on Tuesday, May 13th. Chardan Capital analyst R. Li expects that the company will earn ($1.25) per share for the year. Chardan Capital has a “Buy” rating and a $80.00 price target on the stock. The consensus estimate for Bright Minds Biosciences’ current full-year earnings is ($1.24) per share. Chardan Capital also issued estimates for Bright Minds Biosciences’ FY2026 earnings at ($2.79) EPS.

Several other equities research analysts have also commented on the stock. Cantor Fitzgerald upgraded shares of Bright Minds Biosciences to a “strong-buy” rating in a research note on Tuesday, May 13th. Cowen started coverage on shares of Bright Minds Biosciences in a research note on Tuesday. They issued a “buy” rating on the stock. HC Wainwright restated a “buy” rating and issued a $85.00 price target on shares of Bright Minds Biosciences in a research note on Wednesday, February 19th. Piper Sandler started coverage on shares of Bright Minds Biosciences in a research note on Thursday, January 23rd. They issued an “overweight” rating and a $93.00 price target on the stock. Finally, TD Cowen started coverage on shares of Bright Minds Biosciences in a research note on Tuesday, May 13th. They issued a “buy” rating on the stock. Six equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $83.25.

Bright Minds Biosciences Trading Up 2.0%

Shares of NASDAQ:DRUG opened at $33.00 on Friday. The firm’s 50 day moving average is $32.86 and its two-hundred day moving average is $36.77. Bright Minds Biosciences has a 52 week low of $0.93 and a 52 week high of $79.02. The firm has a market capitalization of $232.45 million, a P/E ratio of -194.11 and a beta of -5.32.

Bright Minds Biosciences (NASDAQ:DRUG) last released its quarterly earnings data on Wednesday, May 21st. The company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.09.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in DRUG. Atika Capital Management LLC bought a new position in shares of Bright Minds Biosciences in the fourth quarter valued at approximately $540,000. Springhill Fund Asset Management HK Co Ltd bought a new position in shares of Bright Minds Biosciences in the fourth quarter valued at approximately $2,185,000. Walleye Capital LLC bought a new position in shares of Bright Minds Biosciences in the fourth quarter valued at approximately $3,717,000. Vivo Capital LLC bought a new stake in Bright Minds Biosciences during the fourth quarter worth approximately $9,062,000. Finally, Adage Capital Partners GP L.L.C. bought a new stake in Bright Minds Biosciences during the fourth quarter worth approximately $4,773,000. 40.52% of the stock is currently owned by institutional investors.

Bright Minds Biosciences Company Profile

Bright Minds Biosciences Inc, a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder.